NCT05599880View on ClinicalTrials.gov

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2027

Conditions
Relapsed/Refractory Immune Thrombocytopenia
Interventions
DRUG

Bortezomib

Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.

Trial Locations (3)

Unknown

RECRUITING

Seoul National University Bundang Hospital, Guri-si

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER